Clinical Trials Logo

Metastatic Renal Cell Cancer clinical trials

View clinical trials related to Metastatic Renal Cell Cancer.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT02542202 Recruiting - Clinical trials for Stage IV Renal Cell Cancer

Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer

Start date: May 1, 2015
Phase: N/A
Study type: Interventional

This pilot clinical trial studies the side effects and best dose of stereotactic body radiation therapy in treating patients with kidney cancer that has spread to other places in the body (metastatic) or has come back (recurrent). Stereotactic radiosurgery, also known as stereotactic body radiation therapy, is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue.

NCT ID: NCT01884961 Recruiting - Clinical trials for Metastatic Renal Cell Cancer

Radiotherapy as an Immunological Booster in Patients With Metastatic Melanoma or Renal Cell Carcinoma Treated With High-dose Interleukin-2

IL2HD
Start date: July 9, 2012
Phase: Phase 2
Study type: Interventional

Title: Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with High-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response Phase: Proof of Principle phase II study Study Design: Single center, open-label trial to assess the immune response and potential biomarkers predictive of response Study Duration: Total duration: 36 months Enrollment: 20 months Treatment: 5 months per patient Follow-up every three months Number of Subjects: Mini-max two-stage Simon design: • Step 1: 7 patients enrolled If tumor antigen-specific immune response is observed in at least 3 patients: • Step 2: recruitment of an additional 12 patients